Pharmacokinetic opportunities for combination therapy in migraine

Neurology

Volumn 64, Issue 10 SUPPL. 2, 2005, Pages

  Fox, Anthony W ^a   Kori, Shashidhar H ^b  

^a EBD Group   (United States)

^b GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; CISAPRIDE; DOPAMINE RECEPTOR BLOCKING AGENT; ERGOT DERIVATIVE; IBUPROFEN; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PHENOTHIAZINE DERIVATIVE; PROCHLORPERAZINE; SEROTONIN 1 AGONIST; SUMATRIPTAN;

CONCENTRATION RESPONSE; DRUG ABSORPTION; DRUG EFFECT; ELECTROLYTE DISTURBANCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MIGRAINE; NEUROLEPTIC MALIGNANT SYNDROME; PHARMACODYNAMICS; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; TARDIVE DYSKINESIA; TORSADE DES POINTES;

EID: 18844449136     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.64.10_suppl_2.s21     Document Type: Review

References (32)

1. Peroutka SJ. Beyond monotherapy: rational polytherapy in migraine. Headache 1998;38:18-22.
2. Mathew NT, Dexter J, Couch J, Flamenbaum W, et al. Dose ranging efficacy and safety of subcutaneous sumatriptan in the acute treatment of migraine. US Sumatriptan Research Group. Arch Neurol 1992;49: 1271-1276.
3. Kaufman JS, Levine I. Acute gastric dilatation of stomach during attack of migraine. Radiology 1936;27:301-302.
4. Géraud G. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Cephalalgia 2001;21:406-407. Abstract.
5. Walls C, Lewis A, Bullman J, et al. Pharmacokinetic profile of a new form of sumatriptan tablets in healthy volunteers. Curr Med Res Opin 2004;20:803-809.
6. Hunt JN, Knox MT. The regulation of gastric emptying of meals containing citric acid and salts of citric acid. J Physiol 1962;163:34-45.
7. Cooke AR, Hunt JN. Absorption of acetylsalicylic acid from unbuffered and buffered gastric contents. Am J Dig Dis 1970;15:95-102.
8. Diener HC, Bussone G, de Liano H, et al., and the EMSASI Group. Placebo-controlled comparison of effervescent acetylsalicylic acid, sumatriptan and ibuprofen in the treatment of migraine attacks. Cephalalgia 2004;24:947-954.
9. Limmroth V, Katsarava Z, Diener HC. Acetylsalicylic acid in the treatment of headache. Cephalalgia 1999;19:545-551.
10. Colman I, Brown MD, Innes GD, Grafstein E, Roberts TE, Rowe BH. Parenteral metoclopramide for acute migraine: meta-analysis of randomized controlled trials. BMJ 2004;329:1369-1372.
11. McCallum RW. Review of the current status of prokinetic agents in gastroenterology. Am J Gastroenterol 1985;80:1008-1016.
12. Orihata M, Sarna SK. Contractile mechanisms of action of gastroprokinetic agents: cisapride, metoclopramide, and domperidone. Am J Physiol 1994;266:G665-676.
13. Greiff JM, Rowbotham D. Pharmacokinetic drug interactions with gastrointestinal motility modifying agents. Clin Pharmacokinet 1994;27: 447-461.
14. van Wyk M, Sommers DK, Moncrieff J. Influence of cisapride, metoclopramide and loperamide on gastric emptying of normal volunteers as measured by means of the area under the curve of the cumulative fraction absorbed-time profile of paracetamol. Methods Find Exp Clin Pharmacol 1992;14:379-382.
15. Tfelt-Hansen P, Henry P, Mulder LJ, Scheldewaert RG, Schoenen J, Chazot G. The effectiveness of combined oral lysine acetylsalicylate and metoclopramide compared with oral sumatriptan for migraine. Lancet 1997;346:923-926.
16. Geraud G, Compagnon A, Rossi A; and the COZAM Study Group. Zolmitriptan versus a combination of acetylsalicylic acid and metoclopramide in the acute oral treatment of migraine: a double-blind, randomised, three-attack study. Eur Neurol 2002;47:88-98.
17. Edwards KR, Norton J, Behnke M. Comparison of intravenous valproate versus intramuscular dihydroergotamine and metoclopramide for acute treatment of migraine. Headache 2001;41:976-980.
18. Gross DW, Donat JR, Boyle CA. Dihydroergotamine and metoclopramide in the treatment of organic headache. Headache 1995;35:637-638.
19. Scherl ER, Wilson JF. Comparison of dihydroergotamine with metoclopramide versus meperidine with promethazine in the treatment of acute migraine. Headache 1995;35:256-259.
20. Schulman E, Dermott KF. Sumatriptan plus metoclopramide in triptan-nonresponsive migraineurs. Headache 2003;43:729-733.
21. Schwarzberg MN. Application of metoclopramide specificity in migraine attacks therapy. Headache 1994;34:439-441.
22. Fox AW. Metoclopramide and sumatriptan. Headache 2004;44:446-447.
23. Houghton LA, Fowler P, Keene ON, Read NW. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man. Aliment Pharmacol Ther 1992;6:685-691.
24. Seaber EJ, Ridout G, Layton G, Posner J, Peck RW. The novel anti-migraine compound zolmitriptan (Zornig, 311C90) has no clinically significant interactions with paracetamol or metoclopramide. Eur J Clin Pharmacol 1997;53:229-234.
25. Spruill SE, Wargin BA, Littlefield DE, Davidson IA, Plachetka JR. The pharmacokinetics and bioavailability of metoclopramide and naproxen from MT100™ tablets. American College of Clinical Pharmacy Annual Scientific Meeting, November 2003. Abstract.
26. Pellegrino R, Littlefield D, Borland J, Spruill S, Plachetka J. Comparative efficacy of MT100 and sumatriptan 50 mg in treating acute migraine subjects with severe pain or nausea at baseline. Poster. http://www.pozen.com; accessed December 31, 2004.
27. Geraud G, Keywood C, Senard JM. Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache 2003;43:376-388.
28. Enger C, Cali C, Walker AM. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. Pharmacoepidemiol Drug Saft 2002;11:477-486.
29. Elming H, Sonne J, Lublin HK. The importance of the QT interval: a review of the literature. Acta Psychiatr Scand 2003;107:96-101.
30. Sharma S, Prasad A, Nehru R, et al. Efficacy and tolerability of prochlorperazine buccal tablets in treatment of acute migraine. Headache 2002;42:896-402.
31. 1B/1D agonists: a model with pharmacokinetic validation. Headache 2004;44:142-147.
32. Duquesnoy C, Mamet JP, Sumner D, Fuseau E. Comparative clinical pharmacokinetics of single doses of sumatriptan following subcutaneous, oral, rectal and intranasal administration. Eur J Pharm Sci 1998; 6:99-104.